Artelo Biosciences, Inc. (ARTL)
5.85
-0.13
(-2.17%)
USD |
NASDAQ |
Sep 10, 15:22
Artelo Biosciences Enterprise Value : 20.90M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 20.90M |
| September 08, 2026 | 21.78M |
| September 04, 2026 | 21.15M |
| September 03, 2026 | 21.90M |
| September 02, 2026 | 23.16M |
| September 01, 2026 | 21.63M |
| August 31, 2026 | 22.49M |
| August 28, 2026 | 20.83M |
| August 27, 2026 | 20.77M |
| August 26, 2026 | 22.64M |
| August 25, 2026 | 22.89M |
| August 24, 2026 | 21.82M |
| August 21, 2026 | 21.94M |
| August 20, 2026 | 22.71M |
| August 19, 2026 | 22.99M |
| August 18, 2026 | 23.36M |
| August 17, 2026 | 23.03M |
| August 14, 2026 | 25.64M |
| August 13, 2026 | 24.45M |
| August 12, 2026 | 23.48M |
| August 11, 2026 | 23.92M |
| August 10, 2026 | 22.43M |
| August 07, 2026 | 23.03M |
| August 06, 2026 | 24.21M |
| August 05, 2026 | 24.17M |
| Date | Value |
|---|---|
| August 04, 2026 | 24.69M |
| August 03, 2026 | 23.85M |
| July 31, 2026 | 24.88M |
| July 30, 2026 | 24.32M |
| July 29, 2026 | 23.12M |
| July 28, 2026 | 29.03M |
| July 27, 2026 | 33.92M |
| July 24, 2026 | 34.30M |
| July 23, 2026 | 35.81M |
| July 22, 2026 | 36.19M |
| July 21, 2026 | 38.07M |
| July 20, 2026 | 38.07M |
| July 17, 2026 | 39.20M |
| July 16, 2026 | 38.82M |
| July 15, 2026 | 39.20M |
| July 14, 2026 | 39.58M |
| July 13, 2026 | 35.43M |
| July 10, 2026 | 36.56M |
| July 09, 2026 | 34.30M |
| July 08, 2026 | 33.41M |
| July 07, 2026 | 33.74M |
| July 06, 2026 | 36.94M |
| July 02, 2026 | 37.69M |
| July 01, 2026 | 37.32M |
| June 30, 2026 | 38.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.859B |
| Corcept Therapeutics, Inc. | 12.19B |
| Veru, Inc. | 19.18M |
| Johnson & Johnson | 671.47B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.427M |
| Total Expenses (Quarterly) | 2.427M |
| EPS Diluted (Quarterly) | -0.8949 |
| Earnings Yield | -392.9% |
| Normalized Earnings Yield | -371.07 |